Clinical Trial Update: Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study evaluating SGN-40 (brentuximab vedotin) in patients with refractory or recurrent multiple m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SGN-40 (dacetuzumab)

Snippet

Sponsor: Seagen Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED